A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

Venugopal, Balaji; Baird, Richard; Kristeleit, Rebecca S; Plummer, Ruth; Cowan, Richard; Stewart, Adam; Fourneau, Nele; Hellemans, Peter; Elsayed, Yusri; McClue, Steve; Smit, Johan W; Forslund, Ann; Phelps, Charles; Camm, John; Evans, T R Jeffry; de Bono, Johann S; Banerji, Udai

Venugopal, Balaji; Baird, Richard; Kristeleit, Rebecca S; Plummer, Ruth; Cowan, Richard; Stewart, Adam; Fourneau, Nele; Hellemans, Peter; Elsayed, Yusri; McClue, Steve; Smit, Johan W; Forslund, Ann; Phelps, Charles; Camm, John; Evans, T R Jeffry; de Bono, Johann S; Banerji, Udai.

Affiliation

Venugopal B; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.

Clin Cancer Res ; 19(15): 4262-72, 2013 Aug 01.

Article in En | MEDLINE | ID: mdl-23741066

Subject(s)

Histone Deacetylase Inhibitors/administration & dosage; Hydroxamic Acids/administration & dosage; Leukocytes, Mononuclear/drug effects; Neoplasms/drug therapy; Administration, Oral; Adult; Aged; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Histone Deacetylase Inhibitors/adverse effects; Histone Deacetylase Inhibitors/pharmacokinetics; Humans; Hydroxamic Acids/adverse effects; Hydroxamic Acids/pharmacokinetics; Maximum Tolerated Dose; Middle Aged; Neoplasms/pathology; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukocytes, Mononuclear / Histone Deacetylase Inhibitors / Hydroxamic Acids / Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Humans / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2013 Document type: Article Affiliation country: United kingdom Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google